Radicava ORS
E561114
Radicava ORS is an oral formulation of the drug edaravone used to slow functional decline in adults with amyotrophic lateral sclerosis (ALS).
Statements (37)
| Predicate | Object |
|---|---|
| instanceOf |
oral formulation
ⓘ
pharmaceutical drug ⓘ |
| administrationSchedule | cyclic dosing regimen ⓘ |
| adverseEffect |
contusion
ⓘ
eczema ⓘ gait disturbance ⓘ headache ⓘ respiratory discomfort ⓘ |
| approvalFor | treatment of ALS ⓘ |
| benefit | oral administration alternative to IV edaravone ⓘ |
| containsChemicalSubstance | edaravone NERFINISHED ⓘ |
| contraindication | known hypersensitivity to edaravone ⓘ |
| countryOfApproval | United States NERFINISHED ⓘ |
| developer | Mitsubishi Tanabe Pharma NERFINISHED ⓘ |
| drugClass | free radical scavenger ⓘ |
| hasAbbreviation | Radicava ORS NERFINISHED ⓘ |
| hasActiveIngredient | edaravone NERFINISHED ⓘ |
| hasBrandName | Radicava ORS NERFINISHED ⓘ |
| hasDosageForm | oral suspension ⓘ |
| indication |
ALS
ⓘ
amyotrophic lateral sclerosis ⓘ |
| isReformulationOf | intravenous edaravone ⓘ |
| legalStatus | prescription only ⓘ |
| marketingAuthorizationHolder | Mitsubishi Tanabe Pharma America NERFINISHED ⓘ |
| mechanismOfAction | acts as an antioxidant to reduce oxidative stress ⓘ |
| pharmaceuticalForm | ready-to-drink oral solution ⓘ |
| pharmacologicalEffect | slows loss of physical function in ALS patients ⓘ |
| regulatoryAgencyApproval | U.S. Food and Drug Administration NERFINISHED ⓘ |
| relatedIntravenousFormulation | Radicava NERFINISHED ⓘ |
| requiresMonitoring | hypersensitivity symptoms ⓘ |
| routeOfAdministration | oral ⓘ |
| storageCondition | store at controlled room temperature ⓘ |
| targetPopulation | adults ⓘ |
| therapeuticArea | neurology ⓘ |
| therapeuticUse | to slow functional decline in adults with ALS ⓘ |
| treatsDisease | motor neuron disease ALS ⓘ |
| warning | may cause hypersensitivity reactions ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Edaravone